November/December 2010

TABLE OF CONTENTS

Decade in Review – Drug Delivery Transactions
Josef Bossart, PhD, has already, in previous installments, looked at the quantitative aspects of the business; product sales, product approvals, and company performance. This month, he takes a more subjective look at the past decade through the lens of transactions.

Self-Delivering RNAi Compounds

James Cardia, PhD; Dmitry Samarsky, PhD; and Tod Woolf, PhD; examine recently developed self-delivering rxRNA, which are novel, covalently modified RNAi compound configurations that do not require a delivery vehicle to enter cells and have improved pharmacology compared to traditional siRNAs.

 

The SAINT^TM Technology for DNA, RNA & Protein Delivery

Marcel H.J. Ruiters, PhD, indicates the SAINT delivery technology meets all the requirements as an ideal delivery system for DNA, RNA, and proteins and therefore believes the technology can greatly contribute to the removal of what today is still the biggest hurdle in DNA/RNA/protein-mediated therapies: delivery.

 

Weekly, Oral Zoledronic Acid Can Improve Quality of Life for Bone Metastases Sufferers

Contributor Cindy H. Dubin reports Orazol has the potential to make an impact on patient care in the years ahead, and the market opportunity for Orazol is substantial and presents compelling potential for major growth.

 

Edge Therapeutics: Transforming Off-Patent Drugs Into Locally Delivered Therapies for Unmet Conditions of the CNS

Executive Summary: Brian Leuthner discusses how Edge Therapeutics plans to translate its preclinical therapies into life-saving medicines by streamlining its path toward clinical efficacy, and the impact the recent Healthcare Reform act may have on Edge’s products and the industry.

 

Company Profiles

For each participating company, this section presents a special 2-page spread featuring core technologies, capabilities, products, and services. Featured companies include:

 

DEPARTMENTS

 

Market News & Trends

 

Advanced Delivery Devices

New Devices for Dispensing Ophthalmic Treatments May Be the Key to Managing the Life Cycles of Established Products

 

Technology Showcase

 

External Delivery

Where’s the Beef?

 

Download Issue

COVER

FEATURES